Interview by Emma Bishop, RARE Revolution,
featuring Steffen Thirstrup, chief medical officer at theEuropean Medicines Agency

“The idea of the Joint Clinical Assessment (JCA) is to agree on a common set of standards to do the technology assessment, which can be taken into the member states as part of the pricing and negotiation. The aim is, of course, to hopefully reduce the time from approval by the EMA to actual access at a national level for patients.” Steffen

---